KZKaikai Zhao

Kaikai Zhao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kaikai Zhao has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Efficacy and safety of omitting the clinical target volume in limited-stage small cell lung cancer: a large-scale multicenter real-world study

    by Xiaolong Wang, Xinrui Yu, Xiaoli Liu, Kaikai Zhao, Yankang Li, Hong Feng, Meili Sun, Jinming Yu, Yu Chen, Xiangjiao Meng

  • Open Access

    Treatment options for EGFR mutation-positive NSCLC patients with leptomeningeal metastases after third-generation TKI resistance: a retrospective real-world study

    by Wenhua Yun, Ailing Liu, Junxu Wen, Kaikai Zhao, Xiangjiao Meng

    Background: Leptomeningeal metastasis (LM) is a serious complication of advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation. There are no guidelines or consensus on the optimal treatment regimens and strategies for LM yet. Objectives: To analyze the influence of different treatment methods on the survival of patients and explore the factors influencing the prognosis of patients with LM. We profiled the cerebrospinal fluid (CSF) immune microenvironment in patients with LM using genetic and lymphocyte subset analyses. Design: We identified 209 patients with advanced NSCLC who developed LM without extracranial progression following third-generation EGFR-tyrosine kinase inhibitor (EGFR-TKIs) therapy. Their medical records were reviewed to extract relevant data. Methods: Survival curves were plotted and prognostic factors were analyzed using R software and SPSS statistical software, respectively. Statistical analysis was performed on the results of CSF genetic testing and lymphocyte subset profiling. Results: The median overall survival (mOS) time of patients who received high-dose EGFR-TKI monotherapy or in combination with other treatments was longer than that of patients with standard-dose EGFR-TKI combined with other treatments (19.7 vs 9.0 months), patients who received EGFR-TKI combined with anti-angiogenic drugs was longer than that of patients who did not combine anti-angiogenic drugs (19.6 vs 12.0 months). Analysis of CSF genomic profiles from 124 patients with LM identified a greater frequency of EGFR L858R (64.5%) versus exon 19 deletions (35.5%). We also observed a significant enrichment of B-cell subsets in the CSF of patients with LM compared to those without, and the B-cell count gradually decreased during the treatment process. Conclusion: For patients developing LM after third-generation EGFR-TKI resistance, high-dose EGFR-TKIs or EGFR-TKIs combined with anti-angiogenic drugs represent viable therapeutic strategies, and B lymphocytes may serve as a promising immunotherapy target for LM.


  • Open Access

    Retrospective prognostic evaluation and single-cell transcriptomic analyses of non-small cell lung carcinoma with malignant pleural effusion

    by Peizhu Wu, Ran Gao, Kaikai Zhao, Xiangjiao Meng

    Background: The impact of malignant pleural effusion (MPE) and intrapleural infusion therapy on the prognosis of non-small cell lung carcinoma (NSCLC) patients receiving immunochemotherapy remains unclear. Investigating the tumor microenvironment of MPE may offer valuable insights for improving outcomes, yet current research in this area is limited. The aim of this study is to explore the impact of MPE and intrapleural infusion therapy on prognosis in the era of immunochemotherapy, and to identify potential therapeutic targets for improving the prognosis of MPE patients. Methods: This study included advanced NSCLC patients without driver mutations who underwent first-line immunochemotherapy at Shandong Cancer Hospital and Institute between December 2018 and June 2023. Progression-free survival (PFS) and overall survival (OS) were the primary endpoints. Propensity score matching (PSM) and survival analysis were performed. Single-cell data of primary tumors (PTs) and MPE were obtained from GSE131907. This study performed cell subpopulation comparison, copy number variation (CNV) analysis of epithelial cells, differential gene expression analysis of malignant cells, gene set variation analysis (GSVA), single-cell regulatory network inference and clustering (SCENIC) analysis, and cell-cell interaction analysis. Results: A total of 116 patients with MPE and 279 patients without MPE were included in this study; after matching, each group included 112 patients. Patients with MPE had significantly shorter median PFS and OS compared to those without MPE (PFS: 8.0 vs. 16.0 months, Pvs. not reached, Pvs. 11.0 months, P=0.09; OS: 20.0 vs. 19.0 months, P=0.77). Genes such as GTSF1, MAGEA3, XIST, and FGB were significantly upregulated in malignant cells from MPE. In the MPE microenvironment, CD4⁺ T cells were the dominant T cell subset, naive B cells were selectively enriched, and monocytes/macrophages made up the majority of myeloid cells. The INTERFERON_ALPHA_RESPONSE pathway was enriched in diverse immune cell types from MPE, although this enrichment might not be statistically significant. Interferon regulatory factor 9 (IRF9) was widely upregulated in T cells, natural killer (NK) cells, B cells, and myeloid cells from MPE. Myeloid cells acted as the primary signal senders and receivers in the MPE microenvironment, while epithelial cells primarily functioned as signal senders. Conclusions: Under immunochemotherapy, NSCLC patients with MPE still demonstrated poor prognosis. This provides an additional prognostic predictor for NSCLC patients receiving standard first-line treatment. However, intrapleural infusion of existing drugs did not improve survival in these patients. The high expression of certain genes in tumor cells from MPE may partly explain this unfavorable outcome. IRF9, which regulates type I interferon (IFN-I) signaling, was upregulated in MPE. Therefore, targeted delivery of IFN-I to the pleural cavity may offer a feasible approach for the treatment of MPE.


  • Open Access

    PortNet: Achieving lightweight architecture and high accuracy in lung cancer cell classification

    by Kaikai Zhao, Youjiao Si, Liangchao Sun, Xiangjiao Meng


  • Open Access

    RNA-seq and bulk RNA-seq data analysis of cancer-related fibroblasts (CAF) in LUAD to construct a CAF-based risk signature

    by Youjiao Si, Zhonghua Zhao, Xiangjiao Meng, Kaikai Zhao

    Angiogenesis, metastasis, and resistance to therapy are all facilitated by cancer-associated fibroblasts (CAFs). A CAF-based risk signature can be used to predict patients’ prognoses for Lung adenocarcinoma (LUAD) based on CAF characteristics. The Gene Expression Omnibus (GEO) database was used to gather signal-cell RNA sequencing (scRNA-seq) data for this investigation. The GEO and TCGA databases were used to gather bulk RNA-seq and microarray data for LUAD. The scRNA-seq data were analyzed using the Seurat R program based on the CAF markers. Our goal was to use differential expression analysis to discover differentially expressed genes (DEGs) across normal and tumor samples in the TCGA dataset. Pearson correlation analysis was utilized to discover prognostic genes related with CAF, followed by univariate Cox regression analysis. Using Lasso regression, a risk signature based on CAF-related prognostic genes was created. A nomogram model was created based on the clinical and pathological aspects. 5 CAF clusters were identified in LUAD, 4 of which were associated with prognosis. From 2811 DEGs, 1002 genes were found to be significantly correlated with CAF clusters, which led to the creation of a risk signature with 8 genes. These 8 genes were primarily connected with 41 pathways, such as antigen paocessing and presentation, apoptosis, and cell cycle. Meanwhile, the risk signature was significantly associated with stromal and immune scores, as well as some immune cells. Multivariate analysis revealed that risk signature was an independent prognostic factor for LUAD, and its value in predicting immunotherapeutic outcomes was confirmed. A novel nomogram integrating the stage and CAF-based risk signature was constructed, which exhibited favorable predictability and reliability in the prognosis prediction of LUAD. CAF-based risk signatures can be effective in predicting the prognosis of LUAD, and they may provide new strategies for cancer treatments by interpreting the response of LUAD to immunotherapy.


  • Open Access

    Correction to: TIGIT blockade enhances tumor response to radiotherapy via a CD103 + dendritic cell-dependent mechanism

    by Kaikai Zhao, Liyang Jiang, Youjiao Si, Shujie Zhou, Zhaoqin Huang, Xiangjiao Meng

  • Open Access

    Geriatric nutritional risk index as a prognostic factor in patients with hepatocellular carcinoma following transarterial chemoembolization: A retrospective study

    by Youjiao Si, Peng Xu, Aihua Xu, Peiyuan Wang, Kaikai Zhao

    The geriatric nutritional risk index (GNRI) has been shown to be associated with the prognosis of cancer patients except for hepatocellular carcinoma (HCC) patients after transarterial chemoembolization (TACE). Our aim is to examine the association between the GNRI and long-term prognosis in patients with HCC who underwent TACE. Patients with HCC who underwent TACE were enrolled. The relationship between the patient characteristics and GNRI were compared, and the independent prognostic factors were investigated. Nomogram performance was assessed via the concordance index (C-index) and calibration plots. Decision curve analysis (DCA) was performed to evaluate the net benefit of the nomogram. A total of 235 patients met the inclusion criteria. Compared with the parameters of the high GNRI group, low GNRI was significantly associated with hypertension, ascites, body mass index, tumor size, anemia, Child-Turcotte-Pugh class. The univariate analysis demonstrated that overall survival (OS) was inferior when GNRI < 98, tumor size ≥ 5cm, vascular invasion, alpha-fetoprotein level ≥ 400, Barcelona clinical liver cancer stage B to C and TACE times < 3. The multivariate analysis revealed that GNRI < 98, tumor size ≥ 5cm, tumor number ≥ 2, alpha-fetoprotein level ≥ 400 and TACE times < 3 were independent predictors of a poor OS. In the validation step, OS was shown to be well calibrated (C-index = 0.724), and a satisfactory clinical utility was proven by DCA. Low GNRI score was associated with a shorter OS in patients undergoing TACE.


  • Open Access

    Sarcopenia is associated with prognosis in patients with esophageal squamous cell cancer after radiotherapy or chemoradiotherapy

    by Junchao Qian, Youjiao Si, Ke Zhou, Yu Tian, Qisen Guo, Kaikai Zhao, Jinming Yu

    Background: This study aimed to determine the prognostic value of the sarcopenia on the progression free survival (PFS) and overall survival (OS) of esophageal squamous cell cancer (ESCC) patients who received radiotherapy (RT) or chemoradiotherapy (CRT). Methods: Data on clinicopathological characteristics and nutritional parameters were analyzed and correlated with PFS and OS, retrospectively. Skeletal muscle, subcutaneous, visceral and total fat tissue cross-sectional areas were evaluated on CT images at the midpoint of the 3rd lumbar vertebrae. A total of 213 patients were enrolled in this study. Results: Sarcopenia was significantly associated with subcutaneous fat content. The univariate analysis demonstrated that OS was superior in patients with non-sarcopenia, non-alcohol, NRI ≥ 100, albumin ≥ 40 g/L, TATI > 83.0, SATI > 27.8, VATI > 49, non-anemia, cervical and upper-thoracic ESCC, T stage 1–2, N stage 0–1 and TNM stage I–II. In the multivariate analysis, sarcopenia, albumin, N stage and TNM stage were identified as independent prognostic factors of survival. This study demonstrated that sarcopenia was related to worse PFS and OS in patients with ESCC who received RT or CRT. Conclusions: Sarcopenia is considered to be a useful predictor in patients with ESCC who received RT or CRT. This study also provided a conceptual basis for further prospective research on the application of the sarcopenia for patients receiving RT or CRT for intermediate- and advanced-stage ESCC.


  • Open Access

    Safety of thoracic radiotherapy after PD‐(L)1 inhibitor treatment in patients with lung cancer

    by Yu Chen, Xinchao Liu, Zhaoqin Huang, Kaikai Zhao, Yao Wang, Fei Ren, Jinming Yu, Xiangjiao Meng

    Background: The safety of thoracic radiotherapy (TRT) after programmed death 1/programmed death ligand 1 (PD‐(L)1) inhibitor treatment in patients with lung cancer was scarcely reported. This retrospective study was conducted to evaluate the incidence, severity, and risk factors of symptomatic treatment‐related pneumonitis in patients with lung cancer who received this sequential combination.Methods: We conducted a retrospective study of a cohort of patients with lung cancer who received TRT after at least two cycles of PD‐(L)1 inhibitor treatment between January 2018 and August 2020. Treatment‐related pneumonitis was evaluated and analyzed to illustrate the safety profile of this sequential combination. Potential risk factors were explored by univariate and multivariate logistic regression analyses.Results: Among the 828 patients with prior PD‐(L)1 inhibitor treatment, 96 patients receiving subsequent TRT were included in the analysis. Of these, 49 patients (51%) received radical TRT while 47 patients (49%) received palliative TRT. The median total dose was 52 Gy (IQR 50–60 Gy). The median time from the initiation of PD‐(L)1 inhibitor treatment to TRT was 4.8 months (1.6–14.1 months) with most of the patients (74%) administering no less than four cycles of PD‐(L)1 inhibitor. During follow‐up, 47 patients (48.96%) developed symptomatic treatment‐related pneumonitis (grade 2 n = 28, grade ≥3 n = 19) while six patients (6.25%) suffered from fatal toxicity. The median time of pneumonitis onset after completion of TRT was 35 days (0–177 days) with six patients developing during TRT. Pulmonary emphysema and lung V20 were demonstrated to be independent risk factors of symptomatic pneumonitis (OR: 5.67, 95% CI: 1.66–19.37, p = 0.006; OR: 3.49, 95% CI: 1.41–8.66, p = 0.007, respectively).Conclusion: TRT after PD‐(L)1 inhibitor treatment resulted in significantly increased incidence and severity of treatment‐related pneumonitis in patients with lung cancer. Intensive attention should be emphasized to the safety of this sequential combination in clinical practice.


  • Open Access

    Efficacy and toxicity of re-irradiation for esophageal cancer patients with locoregional recurrence: a retrospective analysis

    by Kaikai Zhao, Youjiao Si, Liangchao Sun, Xiangjiao Meng, Jinming Yu

    Introduction: There is no standard treatment for locoregional recurrent (LR) esophageal squamous cell carcinoma (ESCC) patients treated with radiotherapy (RT) previously. This retrospective study aimed to examine the efficacy and toxicity of re-irradiation (re-RT) for ESCC patients with LR. Patients and methods: A total of 252 patients were enrolled. Gross tumor volumes for re-RT were defined using contrast enhanced computed tomography and/or positron emission tomography/computed tomography. Overall survival (OS), after recurrence survival (ARS) and toxicities were assessed. Results: Through a median follow-up of 38 months, the median OS and ARS were 39.0 and 13.0 months, respectively. The 6-, 12-, and 24-month ARS rates were 81.9%, 50.5%, and 21.8%, respectively. Multivariate analyses showed that chemotherapy, esophageal stenosis and recurrence-free interval (RFI) may be independent prognostic factors for ARS. The incidence of esophageal fistula/perforation (EP), radiation-induced pneumonitis and esophagorrhagia was 21.4%, 12.8% and 9.1%, respectively. RFI ≤ 12 months, esophageal stenosis and fat space between tumor and adjacent tissue disappeared were independent risk factors for the development of EP after re-RT. Conclusions: Re-RT was feasible for LR ESCC patients after RT initially, the complication occurred in re-RT is acceptable. Patients with RFI ≤ 12 months, esophageal stenosis and fat space between tumor and adjacent tissue disappeared should be closely observed during and after re-RT.